Lapatinib
- TRADE NAME: Tykerb (Novartis)
- INDICATIONS: Breast cancer
- CLASS: Antineoplastic / anticancer agent (see also Immune checkpoint inhibitor), Epidermal growth factor receptor (EGFR) inhibitor / antagonist, HER2/neu receptor antagonist (HER2 receptor antagonist), Tyrosine kinase inhibitor
- HALF-LIFE: 24 hours
Alfuzosin, Artemether/Lumefantrine, Atazanavir, Carbamazepine, Chloroquine, Ciprofloxacin, Clarithromycin, Clozapine, Colchicine, Conivaptan, CYP2C8 substrates, CYP3A4 inhibitors or inducers, Dabigatran, Deferasirox, Dexamethasone, Digoxin, Docetaxel, Dronedarone, Efavirenz, Eplerenone, Everolimus, Fentanyl, Food, Gadobutrol, Grapefruit Juice, Histamine H2-antagonists, Indinavir, Irinotecan, Itraconazole, Ketoconazole, Nefazodone, Nelfinavir, Nilotinib, Omeprazole, P-glycoprotein inducers, Paclitaxel, Pantoprazole, Pazopanib, Phenobarbital, Phenytoin, Pimecrolimus, Pimozide, Posaconazole, Proton pump inhibitors, QT prolonging agents, Quinine, Repaglinide, Rifabutin, Rifampin, Rifapentin, Ritonavir, Rivaroxaban, Safinamide, Salmeterol, Saquinavir, Saxagliptin, Silodosin, St John's Wort, Telithromycin, Tetrabenazine, Thioridazine, Tolvaptan, Topotecan, Voriconazole, Ziprasidone
PREGNANCY CATEGORY: D
Lapitinib is used in conjunction with capecitabine.
See full prescribing information for complete boxed warning.
Please login to see the rest of this drug profile
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of lapatinib in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 07/31/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric